DENTSPLY SIRONA Inc. (XRAY) Receives Overweight Rating from Morgan Stanley

Morgan Stanley restated their overweight rating on shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in a research report released on Friday, October 6th. The brokerage currently has a $69.00 price objective on the medical instruments supplier’s stock, up from their prior price objective of $67.00.

A number of other equities analysts also recently commented on XRAY. BidaskClub downgraded DENTSPLY SIRONA from a buy rating to a hold rating in a research note on Saturday, June 10th. HC Wainwright started coverage on DENTSPLY SIRONA in a research note on Tuesday, July 11th. They issued a buy rating and a $74.00 price target for the company. Credit Suisse Group reissued an outperform rating and issued a $75.00 target price (up previously from $67.00) on shares of DENTSPLY SIRONA in a report on Thursday, July 13th. Zacks Investment Research raised shares of DENTSPLY SIRONA from a hold rating to a buy rating and set a $72.00 target price on the stock in a report on Thursday, July 13th. Finally, Stifel Nicolaus reissued a buy rating and issued a $66.00 target price (down previously from $70.00) on shares of DENTSPLY SIRONA in a report on Thursday, August 10th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $65.89.

Shares of DENTSPLY SIRONA (NASDAQ:XRAY) opened at 59.14 on Friday. The stock’s market capitalization is $13.57 billion. DENTSPLY SIRONA has a one year low of $52.54 and a one year high of $65.68. The stock’s 50 day moving average price is $57.94 and its 200 day moving average price is $61.07.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.65 earnings per share for the quarter, meeting the consensus estimate of $0.65. The company had revenue of $992.70 million during the quarter, compared to the consensus estimate of $1 billion. DENTSPLY SIRONA had a positive return on equity of 7.24% and a negative net margin of 20.57%. The company’s revenue was down 2.9% on a year-over-year basis. During the same period last year, the firm earned $0.76 earnings per share. Equities research analysts predict that DENTSPLY SIRONA will post $2.68 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “DENTSPLY SIRONA Inc. (XRAY) Receives Overweight Rating from Morgan Stanley” was reported by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/markets/dentsply-sirona-inc-xray-rating-reiterated-by-morgan-stanley/1698811.html.

A number of institutional investors have recently bought and sold shares of XRAY. BlackRock Inc. grew its position in DENTSPLY SIRONA by 3,103.7% in the first quarter. BlackRock Inc. now owns 13,891,329 shares of the medical instruments supplier’s stock worth $867,376,000 after buying an additional 13,457,730 shares during the last quarter. Principal Financial Group Inc. grew its position in DENTSPLY SIRONA by 1,445.2% in the first quarter. Principal Financial Group Inc. now owns 5,292,885 shares of the medical instruments supplier’s stock worth $330,488,000 after buying an additional 4,950,337 shares during the last quarter. Clearbridge Investments LLC grew its position in DENTSPLY SIRONA by 34.6% in the first quarter. Clearbridge Investments LLC now owns 5,258,060 shares of the medical instruments supplier’s stock worth $328,313,000 after buying an additional 1,353,040 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in DENTSPLY SIRONA in the first quarter worth approximately $64,184,000. Finally, Renaissance Technologies LLC grew its position in DENTSPLY SIRONA by 246.0% in the first quarter. Renaissance Technologies LLC now owns 1,044,558 shares of the medical instruments supplier’s stock worth $65,222,000 after buying an additional 742,700 shares during the last quarter. Hedge funds and other institutional investors own 93.87% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.